Tokyo, April 3 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061127) titled '[18F]FDG PET in Breast Cancer: Exploratory Investigation of Clinicopathological Significance' on April 1.
Study Type:
Observational
Primary Sponsor:
Institute - Kyoto University
Condition:
Condition - Patients with breast cancer or suspected breast cancerr
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - To explore the clinicopathological significance of [18F]FDG PET imaging in patients with breast cancer, we will conduct an exploratory study investigating its correlations with staging accuracy, tumor characteristics, and the tumor immune microenvironment (TIME).
Basic objectives2 - Others
Eligibility:
Age-lower limit - 18
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Patients with confirmed or suspected breast cancer who underwent [18F]FDG PET imaging (using PET/CT, dedicated breast PET, and/or PET/MR) at the Department of Diagnostic Radiology, Kyoto University Hospital.
Female patients aged 18 years or older.
Key exclusion criteria - Individuals judged unsuitable for the study by the Principal Investigator, Sub-investigator, or Co-investigator.
Target Size - 400
Recruitment Status:
Recruitment status - Enrolling by invitation
Date of protocol fixation - 2022 Year 03 Month 22 Day
Date of IRB - 2022 Year 03 Month 22 Day
Anticipated trial start date - 2022 Year 03 Month 22 Day
Last follow-up date - 2028 Year 03 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000069947
Disclaimer: Curated by HT Syndication.
